Blue Owl Capital Holdings’s Aspire Biopharma Warrant ASBPW Stock Holding History

Blue Owl Capital Holdings’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1K	Hold	50,000	–	–	﹤0.01%	76
2026 Q1	$1K	Hold	50,000	–	–	﹤0.01%	75
2025 Q4	$1K	Hold	50,000	–	–	﹤0.01%	75
2025 Q3	$1.5K	Hold	50,000	–	–	﹤0.01%	68
2025 Q2	$2.23K	Hold	50,000	–	–	﹤0.01%	70
2025 Q1	$3.5K	Hold	50,000	–	–	﹤0.01%	69
2024 Q4	$2.5K	Hold	50,000	–	–	﹤0.01%	74
2024 Q3	$2K	Buy	+50,000	New	+$2.38K	﹤0.01%	106

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Blue Owl Capital Holdings's ASBPW Position: Q2 2026 in Review

Blue Owl Capital Holdings held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 50,000 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #76.

Blue Owl Capital Holdings first reported a position in ASBPW in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.5K in Q1 2025. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Blue Owl Capital Holdings held 50,000 shares of Aspire Biopharma Warrant worth $1K as of Q2 2026.
Blue Owl Capital Holdings left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #76 holding.
Blue Owl Capital Holdings first reported a position in Aspire Biopharma Warrant in Q3 2024 and has held it in 8 quarters since.
Blue Owl Capital Holdings's Aspire Biopharma Warrant position peaked at $3.5K in Q1 2025.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.